Working with the World Health Organization, RTI has developed a tool for assessing the quality of data for NTDs which focuses exclusively on
(1) verifying the quality of reported data, and
(2) assessing the underlying data management and reporting systems for standard program-level output indicators to validate the reported achievements within the health information monitoring and reporting system, as well as identify areas that need strengthening.
WHO/ENVISION, January 2016.
12 January 2016
An article describing the importance of and complexity in distributing ivermectin annually to people affected by onchocerciasis. NPR, January 14, 2016.
Report of ad hoc meeting, convened to respond to requests by national lymphatic filariasis elimination programmes for the best available guidance on: (i) investigating failures of transmission assessment surveys (TAS); and (ii) identifying corrective actions to both prevent and respond to failures.
Responding Failed TAS-eng (1.20 MB)
05 October 2015
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, proudly congratulates William C. Campbell (pictured/Reuters/Brian Snyder), a retired scientist from Merck Research Laboratories, who was jointly named the 2015 Nobel Prize winner in Physiology or Medicine with Satoshi Omura for the discovery of avermectin, which led to Merck’s development of Mectizan (ivermectin), a treatment for river blindness (also known as onchocerciasis) in Africa, Latin America and Yemen.
29 September 2015
Country efforts supported by a major public-private partnership—including The Carter Center/OEPA, PAHO/WHO, and Merck & Co., Inc.’s Mectizan Donation Program—bring the region closer to achieving the elimination goal by 2020.